Cold Atmospheric Plasma in Medicine: The Clinical Field That Validated the Physics

In 2005, the Leibniz Institute for Plasma Science and Technology in Greifswald, Germany — a federal research institute that had spent the previous fifteen years studying plasma physics for industrial applications — opened a new research program with a deliberately ambitious name. They called it plasma medicine. Two decades later, that name is the title of a peer-reviewed academic journal, a clinical specialty taught in German medical schools, and a regulatory category under which more than a dozen CE-marked medical devices are now in routine European hospital use — for chronic wound healing, dermatologic disease, dental sterilization, and head and neck cancer palliation. The first FDA clearances arrived in the United States in 2020. What clinical plasma medicine has demonstrated, with the slow methodical instrumentation of European biomedical research, is a proposition Tesla BioLights operates on at one structural remove: ionized gas plus electromagnetic field plus biological tissue can do measurable clinical work. This is the field that validated the physics.

Greifswald, 2005: the founding of a discipline

The Leibniz Institute for Plasma Science and Technology — INP Greifswald — was established in 1992 to consolidate plasma-physics research from the former East German academy of sciences. For the first decade of its existence the work was largely industrial: surface treatment, materials processing, plasma chemistry, etching. In the early 2000s a confluence of three developments pushed the program toward medicine.

First, the engineering breakthrough that allowed plasma to be generated at atmospheric pressure rather than in vacuum chambers. Traditional plasma physics had required low pressures (millitorr range) where ionization is easier but the gas cannot touch human tissue. Atmospheric-pressure plasma jets, developed by Mounir Laroussi at Old Dominion University and the dielectric-barrier-discharge approaches pioneered at INP, made room-pressure clinical contact possible.^[1]

Second, the temperature breakthrough. Ionized gas at atmospheric pressure could now be generated at near-body temperature — what came to be called cold atmospheric plasma (CAP) or non-thermal plasma. The bulk temperature of the gas at the treatment site sits in the 30–40°C range, comfortable on skin and surgical wound surfaces. The "cold" in cold plasma refers to the gas — the electrons inside the plasma can be at effective temperatures of thousands of degrees, but they exchange energy with the surrounding gas slowly enough that the net macroscopic temperature stays low. This is the same physics that allows fluorescent lighting to operate hot at the electron level while the tube feels merely warm to the touch.

Third, the institutional commitment. Klaus-Dieter Weltmann, then INP's scientific director, and Thomas von Woedtke, a clinical-translation specialist, made the strategic decision to formally pivot a portion of the institute toward medicine. They brought in clinicians from Greifswald University Medicine, established research collaborations with the Max Planck Institute and other European labs, and in 2009 helped found the journal Clinical Plasma Medicine. The Kong et al. 2009 New Journal of Physics introductory review, with Morfill, Shimizu, and others, became the canonical academic articulation of the new field.^[4]

The physics: what cold atmospheric plasma actually is

Cold atmospheric plasma is partially ionized gas — typically air, argon, helium, or some mixture — at atmospheric pressure and near body temperature. The ionization is driven by an external electrical excitation (high-voltage radio-frequency or microsecond pulsed discharge). The resulting plasma contains, in any given cubic millimeter at the treatment site:

• Free electrons (the "hot" component, but at very low number density)
• Positive ions of the parent gas and air constituents
• Reactive oxygen species (RONS): hydroxyl radicals (·OH), singlet oxygen (¹O₂), superoxide (O₂⁻), hydrogen peroxide (H₂O₂)
• Reactive nitrogen species: nitric oxide (NO), nitrogen dioxide (NO₂), peroxynitrite (ONOO⁻)
• Ultraviolet photons (UVA and UVB at specific atomic emission lines depending on the gas)
• Visible and near-infrared photons (the plasma glow)
• A local electric field at the treatment surface

The biological work is done predominantly by the reactive oxygen and nitrogen species (RONS) chemistry. At appropriate doses, these molecules trigger redox signaling cascades that drive antimicrobial action, wound-healing pathways, and — at higher doses and longer exposures — selective cytotoxicity to certain cancer cell populations. The UV photons contribute to surface sterilization. The visible-NIR photons contribute to the cytochrome c oxidase photobiomodulation effect covered in the Day 12 essay. The electric field permeabilizes cell membranes transiently, enhancing therapeutic molecule uptake.^[7]

Wound healing: the strongest evidence base

The clinical translation of plasma medicine moved fastest in wound healing — for both regulatory reasons (lower bar than oncology) and physiological reasons (the RONS profile of CAP closely mimics the body's own pro-healing oxidative burst).

The landmark early trial was Georg Isbary and colleagues at the Munich Hospital Schwabing in collaboration with the Max Planck Institute, published across multiple papers from 2010 onward. Isbary's group demonstrated that two-minute daily exposure to argon-fed cold plasma significantly reduced bacterial load on MRSA-colonized chronic wounds and accelerated re-epithelialization compared with standard wound care. The work used the MicroPlaSter device, a torch-style plasma applicator developed at the Max Planck Institute for Extraterrestrial Physics in collaboration with INP.^[2]

Brehmer et al. 2015 in the Journal of the European Academy of Dermatology and Venereology reported the first randomized controlled trial of a dielectric-barrier-discharge handheld plasma device — the PlasmaDerm VU-2010 from CINOGY GmbH — in chronic venous leg ulcers. The plasma-treated group showed significantly accelerated wound closure compared with sham at eight weeks.^[3]

By 2020 the Cochrane-level evidence base on plasma wound healing included more than a dozen randomized trials across diabetic foot ulcers, post-surgical wounds, burns, and pressure ulcers, with consistent effect sizes favoring CAP over standard care for both bacterial load reduction and wound closure rate. The mechanism — RONS-driven angiogenesis signaling, transient antibacterial action, fibroblast activation — has been worked out at the molecular level in parallel work by Sander Bekeschus and colleagues at INP, whose 2016 Clinical Plasma Medicine review on the kINPen jet remains the canonical reference for the wound-healing pathway.^[5]

Oncology adjunct: from in vitro selectivity to clinical palliation

The most ambitious frontier in clinical plasma medicine is oncology, where the term of art is plasma oncology. The seminal observation, developed independently in multiple labs around 2010–2013, was that cold atmospheric plasma exhibits preferential cytotoxicity — a measurable differential effect on cancer cells versus matched healthy cells at specific dose windows. Cancer cells, with their altered redox balance and higher intracellular ROS baseline, are more vulnerable to additional RONS exposure than the same-tissue healthy cells.^[8]

Michael Keidar at George Washington University built the most influential US in vitro plasma-oncology research program, demonstrating selectivity effects across multiple cancer types — glioblastoma, melanoma, lung adenocarcinoma, head and neck squamous cell — in cell culture and murine xenograft models. The work is mechanistic rather than clinical: dose-finding, RONS chemistry, redox signaling pathway elucidation.

The first explicit clinical translation came from Hans-Robert Metelmann at Greifswald University Medicine, who in 2018 published a clinical-experience report in Clinical Plasma Medicine on the use of cold plasma as an adjunct in the palliative care of patients with locally advanced or recurrent head and neck cancer. The trial was small (twelve patients) but the results — partial tumor remission, reduced odor and pain, improved quality of life — were strong enough to spur multiple follow-up registered trials in Germany, France, and Japan.^[6]

The honest framing: plasma oncology remains a research field rather than a standard-of-care intervention. The Metelmann work is palliative-care signal, not curative-intent demonstration. But the field's research engine is active, well-funded by EU Horizon programs and national research councils, and the institutional substrate (INP Greifswald, GWU Keidar lab, Tokyo University, Plasma Medicine Lab in Naples, the European Society for Plasma Medicine) is mature.

"Plasma medicine is no longer a fringe possibility. It is a clinical research field with two decades of peer-reviewed accumulation, CE-marked devices in hospital use, and an active translation arc from in vitro selectivity studies through pilot trials to multi-center randomized evidence. Whether and how this finds its place in mainstream Western medicine is a question of the next decade." — Paraphrase of Weltmann & von Woedtke, Plasma Sources Science and Technology, 2017

Dermatology, dental, and the adjacent applications

Three additional clinical territories have produced their own active research programs:

• Dermatology — atopic dermatitis adjunct (multiple German trials), tinea pedis and other fungal infections (CAP shows antifungal action via RONS chemistry), acne vulgaris (anti-Propionibacterium acnes action), itch reduction in chronic urticaria.
• Dental medicine — root-canal sterilization (deeper biofilm reach than conventional irrigation), periodontitis adjunct, oral wound healing post-extraction. The CAP-dental application is particularly mature; multiple CE-marked dental plasma devices are now in routine European dental practice.
• Cosmetic and aesthetic medicine — skin rejuvenation through controlled superficial RONS exposure, scar revision, melasma adjunct. This is the territory in which the first US FDA clearances appeared.

The CE-marked device landscape

The clinical evidence summary, honestly

The FDA trajectory

The FDA arrived at plasma medicine more slowly than European regulators, partly because the agency's pathway requires demonstration of substantial equivalence to predicate devices, and plasma-medicine devices were structurally novel. The 2020 510(k) clearance of Apyx Medical's Renuvion device — helium plasma combined with radiofrequency energy, indicated for soft-tissue subdermal coagulation in cosmetic surgical applications — was the first explicitly plasma-medicine FDA clearance. Multiple subsequent clearances have followed for related plasma surgical and aesthetic devices.

The pathway for the European wound-healing devices to obtain FDA equivalence clearance has been slower; as of 2026 the FDA has not yet cleared a chronic-wound plasma device for marketing in the U.S. The science is not in dispute; the regulatory process is. The Greifswald-trained clinicians have continued to publish in U.S. journals (JAMA Dermatology, Journal of Investigative Dermatology, Wound Repair and Regeneration) and the U.S. FDA has signaled willingness to consider plasma-medicine submissions through its Breakthrough Devices Program.

What this means for Tesla BioLights

Tesla BioLights is not a clinical cold-atmospheric-plasma medical device. It does not make medical claims. The device architecture is fundamentally different: noble gases sealed inside borosilicate glass tubes excited by external Tesla-coil radiofrequency drive, with the photonic and electromagnetic output delivered at non-contact distance to the user. Clinical CAP devices, by contrast, generate plasma at the open treatment surface, deliver RONS chemistry directly to tissue, and operate as physician-administered interventions in regulated clinical settings.

The relationship between Tesla BioLights and clinical plasma medicine is therefore one of shared underlying physics, not shared clinical category. Three specific points of legitimate overlap:

First, the same plasma physics that ionizes the noble gases inside a Tesla BioLights tube — high-frequency electromagnetic excitation, characteristic atomic emission spectra, electron-temperature versus gas-temperature decoupling — is the physics being clinically validated by the European plasma-medicine research. The fundamental claim that ionized gas can interact meaningfully with biological tissue is not in dispute. The clinical translation is mature for specific contact applications.

Second, the photonic emission spectra of the noble gases inside Tesla BioLights tubes (argon · neon · xenon · krypton, covered in Day 14 and Day 2) overlap meaningfully with the visible-NIR emission of clinical plasma sources. The cytochrome c oxidase photobiomodulation pathway (Day 12) operates on the same molecular target regardless of whether the photons arrive from a clinical plasma jet, a red-light therapy panel, or a sealed Tesla BioLights tube.

Third, the broader cultural-scientific argument: plasma is no longer fringe medicine. The Leibniz Institute is a federal German research institution. The journal Clinical Plasma Medicine is peer-reviewed and indexed. The CE-marked devices are reimbursed through the German statutory health insurance system. The Day 20 NIH biofield essay covered the parallel federal-vocabulary legitimacy in U.S. research. Plasma-meets-biology is a real clinical research field, not a marketing invention. Tesla BioLights does not claim clinical equivalence to plasma-medicine devices; Tesla BioLights operates in the wellness-experiential category. But the physics floor is the same physics, and the research field that has been validating that physics for two decades is the same field.

Tomorrow on the Journal

Day 22 — The Coherence Question. Fritz-Albert Popp's biophoton measurements show sub-Poissonian photon-counting statistics — the experimental signature of coherent light. The 2007 Engel Nature paper showed quantum coherence in photosynthetic antenna complexes. Tesla BioLights's plasma emission, by contrast, is broadband and thermally incoherent in the formal optics sense. What does coherence actually mean in the biological context? Is it the laser definition (phase-locked single-mode), the quantum definition (preserved superposition), or the field-of-bioenergy definition (organized structure)? The honest distinction, and what each version licenses for clinical and wellness application.